Multifunctional Alendronate‐PEI Carbon Dots for the Treatment of Bone‐Destructive Diseases via Bidirectional Regulation of Osteoblast‐Osteoclast Function. Issue 2 (18th October 2022)
- Record Type:
- Journal Article
- Title:
- Multifunctional Alendronate‐PEI Carbon Dots for the Treatment of Bone‐Destructive Diseases via Bidirectional Regulation of Osteoblast‐Osteoclast Function. Issue 2 (18th October 2022)
- Main Title:
- Multifunctional Alendronate‐PEI Carbon Dots for the Treatment of Bone‐Destructive Diseases via Bidirectional Regulation of Osteoblast‐Osteoclast Function
- Authors:
- Zhang, Kai
Da, Junlong
Wang, Jianqun
Liu, Lixue
Liu, Xinpeng
Yuan, Haoze
Jiang, Lili
Geng, Yawei
Liu, Xiaoyao
Jiang, Zhuling
Jin, Han
Li, Ying
Zhang, Bin - Abstract:
- Abstract: Bone damage results from the imbalance of bone homeostasis maintained by osteoblast‐regulated bone formation and osteoclast‐mediated bone resorption. Conventional drug therapy and gene therapy may not optimally regulate the bone remodeling process due to the unitary pharmacological mechanism of drug and the safety and targeting of gene vectors. In the present study, multifunctional fluorescent alendronate‐polyethyleneimine carbon dots (Alen‐PEI CDs) are innovatively synthesized, which have excellent biocompatibility, selective bone targeting, gene carrying capacity, and anti‐bone absorption effect. As gene vectors, bone morphogenic protein 2 (BMP2) gene‐loaded Alen‐PEI CDs greatly enhance osteoblast differentiation and bone regeneration. Notably, Alen‐PEI CDs are found to directly inhibit the formation and function of osteoclasts, effectively attenuating the LPS‐induced skull osteolysis in mice. Furthermore, their cumulative toxicity is lower than that of Alen, indicating their potential as an anti‐bone resorptive nanodrug. These results show that the bone‐targeting Alen‐PEI CDs significantly reverse the imbalance of bone homeostasis through a dual‐directional mechanism—directly suppressing bone resorption and indirectly inducing bone formation by transfection of osteogenic therapeutic genes. Overall, the study expands the application for carbon dots in biomedicine, providing new insights for the further development of novel selectively targeted multifunctionalAbstract: Bone damage results from the imbalance of bone homeostasis maintained by osteoblast‐regulated bone formation and osteoclast‐mediated bone resorption. Conventional drug therapy and gene therapy may not optimally regulate the bone remodeling process due to the unitary pharmacological mechanism of drug and the safety and targeting of gene vectors. In the present study, multifunctional fluorescent alendronate‐polyethyleneimine carbon dots (Alen‐PEI CDs) are innovatively synthesized, which have excellent biocompatibility, selective bone targeting, gene carrying capacity, and anti‐bone absorption effect. As gene vectors, bone morphogenic protein 2 (BMP2) gene‐loaded Alen‐PEI CDs greatly enhance osteoblast differentiation and bone regeneration. Notably, Alen‐PEI CDs are found to directly inhibit the formation and function of osteoclasts, effectively attenuating the LPS‐induced skull osteolysis in mice. Furthermore, their cumulative toxicity is lower than that of Alen, indicating their potential as an anti‐bone resorptive nanodrug. These results show that the bone‐targeting Alen‐PEI CDs significantly reverse the imbalance of bone homeostasis through a dual‐directional mechanism—directly suppressing bone resorption and indirectly inducing bone formation by transfection of osteogenic therapeutic genes. Overall, the study expands the application for carbon dots in biomedicine, providing new insights for the further development of novel selectively targeted multifunctional nanodrugs for the treatment of bone‐destructive diseases. Abstract : In this study, novel multifunctional alendronate (Alen)‐polyethyleneimine (PEI) carbon dots (Alen‐PEI CDs) are prepared. It is found that the bone‐targeting Alen‐PEI CDs significantly reverse the imbalance of bone homeostasis through dual‐directional mechanism of directly suppressing bone resorption and indirectly inducing bone formation by transfection of osteogenic therapeutic genes. In the future, Alen‐PEI CDs have potential as a new nanodrug. … (more)
- Is Part Of:
- Advanced therapeutics. Volume 6:Issue 2(2023)
- Journal:
- Advanced therapeutics
- Issue:
- Volume 6:Issue 2(2023)
- Issue Display:
- Volume 6, Issue 2 (2023)
- Year:
- 2023
- Volume:
- 6
- Issue:
- 2
- Issue Sort Value:
- 2023-0006-0002-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-10-18
- Subjects:
- bone homeostasis -- bone‐targeting -- carbon dots -- gene vectors
Therapeutics -- Periodicals
Pharmaceutical technology -- Periodicals
Pharmacogenetics -- Periodicals
615.5 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/23663987 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/adtp.202200149 ↗
- Languages:
- English
- ISSNs:
- 2366-3987
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0696.935580
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25973.xml